临床麻醉学杂志
臨床痳醉學雜誌
림상마취학잡지
THE JOURNAL OF CLINICAL ANESTHESIOLOGY
2014年
6期
584-585
,共2页
米库氯铵%琥珀胆碱%阿曲库铵%无抽搐电休克
米庫氯銨%琥珀膽堿%阿麯庫銨%無抽搐電休剋
미고록안%호박담감%아곡고안%무추휵전휴극
Mivacurium%Succinylcholine%Atracurium%Modified electric convulsive therapy
目的:观察米库氯铵与琥珀胆碱、阿曲库铵在无抽搐电休克治疗(MECT)中的应用。方法选择精神分裂症患者60例,年龄18~60岁,ASA Ⅰ或Ⅱ级,随机分为米库氯铵组(A 组)、琥珀胆碱组(B 组)和阿曲库铵组(C 组),每组20例。分别观察记录诱导后肌松药起效时间、MECT 后自主呼吸恢复时间、患者完全清醒时间及 MECT 诱导前和治疗后5 min MAP、HR、SpO2的变化。结果 B 组肌松起效时间、自主呼吸恢复时间明显短于 A 组和 C 组(P <0.05)。A 组肌松起效时间、自主呼吸恢复时间明显短于 C 组(P <0.05)。结论在无琥珀胆碱或应用琥珀胆碱禁忌的情况下,米库氯铵是行 MECT 较好替代药物。
目的:觀察米庫氯銨與琥珀膽堿、阿麯庫銨在無抽搐電休剋治療(MECT)中的應用。方法選擇精神分裂癥患者60例,年齡18~60歲,ASA Ⅰ或Ⅱ級,隨機分為米庫氯銨組(A 組)、琥珀膽堿組(B 組)和阿麯庫銨組(C 組),每組20例。分彆觀察記錄誘導後肌鬆藥起效時間、MECT 後自主呼吸恢複時間、患者完全清醒時間及 MECT 誘導前和治療後5 min MAP、HR、SpO2的變化。結果 B 組肌鬆起效時間、自主呼吸恢複時間明顯短于 A 組和 C 組(P <0.05)。A 組肌鬆起效時間、自主呼吸恢複時間明顯短于 C 組(P <0.05)。結論在無琥珀膽堿或應用琥珀膽堿禁忌的情況下,米庫氯銨是行 MECT 較好替代藥物。
목적:관찰미고록안여호박담감、아곡고안재무추휵전휴극치료(MECT)중적응용。방법선택정신분렬증환자60례,년령18~60세,ASA Ⅰ혹Ⅱ급,수궤분위미고록안조(A 조)、호박담감조(B 조)화아곡고안조(C 조),매조20례。분별관찰기록유도후기송약기효시간、MECT 후자주호흡회복시간、환자완전청성시간급 MECT 유도전화치료후5 min MAP、HR、SpO2적변화。결과 B 조기송기효시간、자주호흡회복시간명현단우 A 조화 C 조(P <0.05)。A 조기송기효시간、자주호흡회복시간명현단우 C 조(P <0.05)。결론재무호박담감혹응용호박담감금기적정황하,미고록안시행 MECT 교호체대약물。
Objective To observe the effect of mivacurium,succinylcholine and atracurium in modified electric convulsive therapy (MECT).Methods Sixty ASA Ⅰ or Ⅱ patients with schizo-phrenia aged from 18 to 60 years old were randomly divided into 3 groups :mivacurium group (group A,n=20),succinylcholine group (group B,n=20),atracurium group (group C,n=20).The on-set time of muscle relaxation,the recovery time of spontaneous breathing after MECT,the awake time,as well as the changes of 5 min MAP,HR and SpO2 before and after MECT were observed re-spectively.Results The onset time of muscle relaxation and the recovery time of spontaneous breath-ing in group B were shorter than those in groups A and C (P <0.05).The onset time of muscle re-laxation and the recovery time of spontaneous breathing in group A were shorter than those in group C (P <0.05).Conclusion Mivacurium is a better alternative medicine in MECT in the situation of no succinylcholine or succnylcholine contraindication.